Stock comparison

LLYvsRGC

Eli Lilly and CovsRegencell Bioscience Holdings Ltd. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

LLY

Eli Lilly and Co

$917.65

-12.96%

Pharmaceuticals$884.0BNYSE

RGC

Regencell Bioscience Holdings Ltd

$28.31

+70.54%

Pharmaceuticals$11.9BNASDAQ

60-day price, rebased to 100

LLY -11.52% · RGC -12.33%

Round-by-round

LLY 3·RGC 1· 2ties

Tie

Valuation upside

-70.70% vs — to DCF fair value

EdgeRGC

Balance-sheet strength

Altman Z 8.14 vs 32636.93

EdgeLLY

Fundamental quality

Piotroski 8.00 vs 4.00 (of 9)

Tie

Growth + margins

Rule-of-40 53.90 vs —

EdgeLLY

60-day momentum

-11.52% vs -12.33% price return

EdgeLLY

Market-cap liquidity

$884.0B vs $11.9B

Verdict

Across6categories,LLYtakes the edge with3wins to1 (and 2 ties). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onLLYorRGC

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.